Source-grounded facts extracted from Damora Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Brian Burkavage was appointed as principal financial officer and principal accounting officer at Damora Therapeutics, Inc..
“the Board appointed Brian Burkavage, the Company’s current Senior Vice President, Finance, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Time.”
Lori Firmani departed as Chief Financial Officer at Damora Therapeutics, Inc..
“the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.”
Damora Therapeutics, Inc. engaged Ernst & Young LLP as its auditor.
“On April 17, 2026, the Audit Committee engaged Ernst & Young LLP (“EY US”) as the Company’s independent registered public accounting firm, effective immediately.”
Damora Therapeutics, Inc. dismissed EY Godkendt Revisionspartnerselskab as its auditor.
“On April 17, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Damora Therapeutics, Inc., a Delaware corporation (the “Company”), dismissed EY Godkendt Revisionspartnerselskab (“EY Denmark”) as the Company’s independent registered public accounting firm, effective immediately.”
Damora Therapeutics, Inc.: Amended certificate of incorporation to change company name from Galecto, Inc. to Damora Therapeutics, Inc (effective 2026-03-10).
“On March 6, 2026, the Company filed with the Secretary of State of the State of Delaware an amendment to its Amended and Restated Certificate of Incorporation to change the name of the Company from "Galecto, Inc." to "Damora Therapeutics, Inc." (the "Name Change Amendment"). The Name Change Amendment became effective at 12:01 a.m. Eastern Time on March 10, 2026.”
Damora Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC and Leerink Partners LLC, as the representatives of the several underwriters named therein valued at approximately $295.9 million (effective 2026-02-10).
“On February 10, 2026, Galecto, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC, as the representatives of the several underwriters named therein (the “Underwriters”), relating to the offer and sale (the “Offering”) of 14,473,685 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), at a public offering price of $19.00 per share.”
Damora Therapeutics, Inc.: Certificate of Amendment to increase authorized shares of common stock from 300,000,000 to 500,000,000, effective upon filing on February 9, 2026 (effective 2026-02-09).
“On February 9, 2026, in connection with the approval by stockholders of the Company at a special meeting of stockholders (the “Special Meeting”) as described in Item 5.07 below, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, par value $0.00001 per share (“Common Stock”), from 300,000,000 to 500,000,000, which became effective upon filing.”
Damora Therapeutics, Inc.: Corrected authorized shares of Series C Preferred Stock from 43,855 to 43,882 (effective 2025-12-05).
“On December 5, 2025, the Company filed with the Delaware Secretary of State a Certificate of Correction (the “Certificate of Correction”) to the Certificate of Designation of Series C Preferred Stock to correct an inadvertent error in the number of shares of Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the “Series C Preferred Stock”), that the Company is authorized to issue by modifying Section 2 of the Certificate of Designation of Series C Preferred Stock to correctly state that the number of authorized shares of Series C Preferred Stock is 43,882 shares instead of 43,855 shares.”
Damora Therapeutics, Inc.: Filed Certificates of Designation for Series B and Series C Preferred Stock, creating new stock series with specific rights and limitations (effective 2025-11-07).
“On November 7, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock (the “Certificate of Designation of Series B Preferred Stock”) and a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the “Certificate of Designation of Series C Preferred Stock,” and together with the Certificate of Designation of Series B Preferred Stock, the “Certificates of Designation”) in connection with the Merger and the Financing referenced in Item 1.01 above.”
Damora Therapeutics, Inc. completed an acquisition involving Damora Therapeutics, Inc. (closed 2025-11-10).
“On November 10, 2025, the Company completed its business combination with Damora.”
Amy Wechsler was appointed as Director at Damora Therapeutics, Inc..
“appointed Amy Wechsler to join the Board, effective as of October 11, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.